On March 8, 2022 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and best-in-class allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," reported it will present additional pre-clinical data on the company’s CBL-B program in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13, 2022, in New Orleans, LA (Press release, HotSpot Therapeutics, MAR 8, 2022, View Source [SID1234609720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: A novel allosteric CBL-B inhibitor with differentiated immune enhancing activity in preclinical models
Session Category: Immunology
Session Title: Immune Checkpoints
Session Date and Time: Sun., Apr. 10, 2022, 1:30-5:00 PM ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Poster Board Number: 8
Abstract Number: 598